-
1
-
-
33645526144
-
Cancer statistics, 2006
-
Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C, et al. Cancer statistics, 2006. CA Cancer J Clin 2006;56:106-30.
-
(2006)
CA Cancer J Clin
, vol.56
, pp. 106-130
-
-
Jemal, A.1
Siegel, R.2
Ward, E.3
Murray, T.4
Xu, J.5
Smigal, C.6
-
3
-
-
0032497522
-
Bilateral orchiectomy with or without flutamide for metastatic prostate cancer
-
Eisenberger MA, Blumenstein BA, Crawford ED, Miller G, McLeod DG, Loehrer PJ, et al. Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. N Engl J Med 1998;339: 1036-42.
-
(1998)
N Engl J Med
, vol.339
, pp. 1036-1042
-
-
Eisenberger, M.A.1
Blumenstein, B.A.2
Crawford, E.D.3
Miller, G.4
McLeod, D.G.5
Loehrer, P.J.6
-
4
-
-
58949101975
-
In vivo knockdown of the androgen receptor results in growth inhibition and regression of well-established, castration-resistant prostate tumors
-
Snoek R, Cheng H, Margiotti K, Wafa LA, Wong CA, Wong EC, et al. In vivo knockdown of the androgen receptor results in growth inhibition and regression of well-established, castration-resistant prostate tumors. Clin Cancer Res 2009;15:39-47.
-
(2009)
Clin Cancer Res
, vol.15
, pp. 39-47
-
-
Snoek, R.1
Cheng, H.2
Margiotti, K.3
Wafa, L.A.4
Wong, C.A.5
Wong, E.C.6
-
5
-
-
65549168746
-
Anovel androgen receptor splice variant is up-regulated during prostate cancer progression and promotes androgen depletion-resistant growth
-
Guo Z, Yang X, Sun F, Jiang R, Linn DE, Chen H, et al. Anovel androgen receptor splice variant is up-regulated during prostate cancer progression and promotes androgen depletion-resistant growth. Cancer Res 2009;69:2305-13.
-
(2009)
Cancer Res
, vol.69
, pp. 2305-2313
-
-
Guo, Z.1
Yang, X.2
Sun, F.3
Jiang, R.4
Linn, D.E.5
Chen, H.6
-
6
-
-
79960979238
-
Increased androgen receptor transcription: A cause of castration-resistant prostate cancer and a possible therapeutic target
-
Shiota M, Yokomizo A, Naito S. Increased androgen receptor transcription: a cause of castration-resistant prostate cancer and a possible therapeutic target. J Mol Endocrinol 2011;47: R25-41.
-
(2011)
J Mol Endocrinol
, vol.47
-
-
Shiota, M.1
Yokomizo, A.2
Naito, S.3
-
7
-
-
77955296562
-
Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variant
-
Sun S, Sprenger CC, Vessella RL, Haugk K, Soriano K, Mostaghel EA, et al. Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variant. J Clin Invest 2010;120:2715-30.
-
(2010)
J Clin Invest
, vol.120
, pp. 2715-2730
-
-
Sun, S.1
Sprenger, C.C.2
Vessella, R.L.3
Haugk, K.4
Soriano, K.5
Mostaghel, E.A.6
-
8
-
-
51049098138
-
Androgen levels increase by intratumoral de novo steroidogenesis during progression of castration-resistant prostate cancer
-
Locke JA, Guns ES, Lubik AA, Adomat HH, Hendy SC, Wood CA, et al. Androgen levels increase by intratumoral de novo steroidogenesis during progression of castration-resistant prostate cancer. Cancer Res 2008;68:6407-15.
-
(2008)
Cancer Res
, vol.68
, pp. 6407-6415
-
-
Locke, J.A.1
Guns, E.S.2
Lubik, A.A.3
Adomat, H.H.4
Hendy, S.C.5
Wood, C.A.6
-
9
-
-
0035496220
-
The development of androgen-independent prostate cancer
-
Feldman BJ, Feldman D. The development of androgen-independent prostate cancer. Nat Rev Cancer 2001;1:34-45.
-
(2001)
Nat Rev Cancer
, vol.1
, pp. 34-45
-
-
Feldman, B.J.1
Feldman, D.2
-
10
-
-
4944246790
-
Targeting the androgen receptor: Improving outcomes for castration-resistant prostate cancer
-
Scher HI, Buchanan G, Gerald W, Butler LM, Tilley WD. Targeting the androgen receptor: improving outcomes for castration-resistant prostate cancer. Endocr Relat Cancer 2004;11:459-76.
-
(2004)
Endocr Relat Cancer
, vol.11
, pp. 459-476
-
-
Scher, H.I.1
Buchanan, G.2
Gerald, W.3
Butler, L.M.4
Tilley, W.D.5
-
11
-
-
65649090203
-
Development of a second-generation antiandrogen for treatment of advanced prostate cancer
-
Tran C, Ouk S, Clegg NJ, Chen Y, Watson PA, Arora V, et al. Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science 2009;324:787-90.
-
(2009)
Science
, vol.324
, pp. 787-790
-
-
Tran, C.1
Ouk, S.2
Clegg, N.J.3
Chen, Y.4
Watson, P.A.5
Arora, V.6
-
12
-
-
77952105685
-
Antitumour activity of MDV3100 in castration-resistant prostate cancer: A phase 1-2 study
-
Scher HI, Beer TM, Higano CS, Anand A, Taplin ME, Efstathiou E, et al. Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study. Lancet 2010;375:1437-46.
-
(2010)
Lancet
, vol.375
, pp. 1437-1446
-
-
Scher, H.I.1
Beer, T.M.2
Higano, C.S.3
Anand, A.4
Taplin, M.E.5
Efstathiou, E.6
-
13
-
-
84866770294
-
Increased survival with enzalutamide in prostate cancer after chemotherapy
-
Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, Miller K, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 2012;367:1187-97.
-
(2012)
N Engl J Med
, vol.367
, pp. 1187-1197
-
-
Scher, H.I.1
Fizazi, K.2
Saad, F.3
Taplin, M.E.4
Sternberg, C.N.5
Miller, K.6
-
14
-
-
84866752875
-
Emerging targeted therapies for castration-resistant prostate cancer
-
Adamo V, Noto L, Franchina T, Chiofalo G, Picciotto M, Toscano G, et al. Emerging targeted therapies for castration-resistant prostate cancer. Front Endocrinol 2012;3:73.
-
(2012)
Front Endocrinol
, vol.3
, pp. 73
-
-
Adamo, V.1
Noto, L.2
Franchina, T.3
Chiofalo, G.4
Picciotto, M.5
Toscano, G.6
-
15
-
-
80455162581
-
Discovery of aryloxy tetramethylcyclobutanes as novel androgen receptor antagonists
-
Guo C, Linton A, Kephart S, Ornelas M, Pairish M, Gonzalez J, et al. Discovery of aryloxy tetramethylcyclobutanes as novel androgen receptor antagonists. J Med Chem 2011;54:7693-704.
-
(2011)
J Med Chem
, vol.54
, pp. 7693-7704
-
-
Guo, C.1
Linton, A.2
Kephart, S.3
Ornelas, M.4
Pairish, M.5
Gonzalez, J.6
-
16
-
-
0038756444
-
Castration-induced increases in insulin-like growth factor-binding protein 2 promotes proliferation of androgen-independent human prostate LNCaP tumors
-
Kiyama S, Morrison K, Zellweger T, Akbari M, Cox M, Yu D, et al. Castration-induced increases in insulin-like growth factor-binding protein 2 promotes proliferation of androgen-independent human prostate LNCaP tumors. Cancer Res 2003;63:3575-84.
-
(2003)
Cancer Res
, vol.63
, pp. 3575-3584
-
-
Kiyama, S.1
Morrison, K.2
Zellweger, T.3
Akbari, M.4
Cox, M.5
Yu, D.6
-
17
-
-
79954624502
-
A novel HSP90 inhibitor delays castrate-resistant prostate cancer without altering serum PSA levels and inhibits osteoclastogenesis
-
Lamoureux F, Thomas C, Yin MJ, Kuruma H, Fazli L, Gleave ME, et al. A novel HSP90 inhibitor delays castrate-resistant prostate cancer without altering serum PSA levels and inhibits osteoclastogenesis. Clin Cancer Res 2011;17:2301-13.
-
(2011)
Clin Cancer Res
, vol.17
, pp. 2301-2313
-
-
Lamoureux, F.1
Thomas, C.2
Yin, M.J.3
Kuruma, H.4
Fazli, L.5
Gleave, M.E.6
-
18
-
-
35948950583
-
Cooperative interactions between androgen receptor (AR) and heatshock protein 27 facilitate AR transcriptional activity
-
Zoubeidi A, Zardan A, Beraldi E, Fazli L, Sowery R, Rennie P, et al. Cooperative interactions between androgen receptor (AR) and heatshock protein 27 facilitate AR transcriptional activity. Cancer Res 2007;67:10455-65.
-
(2007)
Cancer Res
, vol.67
, pp. 10455-10465
-
-
Zoubeidi, A.1
Zardan, A.2
Beraldi, E.3
Fazli, L.4
Sowery, R.5
Rennie, P.6
-
19
-
-
0026602518
-
Serum prostate specific antigen levels in mice bearinghuman prostate LNCaP tumors are determined by tumor volume and endocrine and growth factors
-
Gleave ME, Hsieh JT, Wu HC, von Eschenbach AC, Chung LW. Serum prostate specific antigen levels in mice bearinghuman prostate LNCaP tumors are determined by tumor volume and endocrine and growth factors. Cancer Res 1992;52:1598-605.
-
(1992)
Cancer Res
, vol.52
, pp. 1598-1605
-
-
Gleave, M.E.1
Hsieh, J.T.2
Wu, H.C.3
Von Eschenbach, A.C.4
Chung, L.W.5
-
20
-
-
70349395222
-
Anti-androgens and androgen-depleting therapies in prostate cancer: New agents for an established target
-
Chen Y, Clegg NJ, Scher HI. Anti-androgens and androgen-depleting therapies in prostate cancer: new agents for an established target. Lancet Oncol 2009;10:981-91.
-
(2009)
Lancet Oncol
, vol.10
, pp. 981-991
-
-
Chen, Y.1
Clegg, N.J.2
Scher, H.I.3
-
21
-
-
0035328474
-
Amplification and overexpression of androgen receptor gene in hormone-refractory prostate cancer
-
Linja MJ, Savinainen KJ, Saram€aki OR, Tammela TL, Vessella RL, Visakorpi T. Amplification and overexpression of androgen receptor gene in hormone-refractory prostate cancer. Cancer Res 2001;61: 3550-5.
-
(2001)
Cancer Res
, vol.61
, pp. 3550-3555
-
-
Linja, M.J.1
Savinainen, K.J.2
Saramaki, O.R.3
Tammela, T.L.4
Vessella, R.L.5
Visakorpi, T.6
-
22
-
-
1542574202
-
Gene expression analysis of human prostate carcinoma during hormonal therapy identifies androgen-responsive genes and mechanisms of therapy resistance
-
Holzbeierlein J, Lal P, LaTulippe E, Smith A, Satagopan J, Zhang L, et al. Gene expression analysis of human prostate carcinoma during hormonal therapy identifies androgen-responsive genes and mechanisms of therapy resistance. Am J Pathol 2004;164: 217-27.
-
(2004)
Am J Pathol
, vol.164
, pp. 217-227
-
-
Holzbeierlein, J.1
Lal, P.2
Latulippe, E.3
Smith, A.4
Satagopan, J.5
Zhang, L.6
-
23
-
-
33645056171
-
Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer
-
Stanbrough M, Bubley GJ, Ross K, Golub TR, Rubin MA, Penning TM, et al. Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer. Cancer Res 2006;66:2815-25.
-
(2006)
Cancer Res
, vol.66
, pp. 2815-2825
-
-
Stanbrough, M.1
Bubley, G.J.2
Ross, K.3
Golub, T.R.4
Rubin, M.A.5
Penning, T.M.6
-
24
-
-
0030024517
-
Androgen receptor status of lymph node metastases from prostate cancer
-
Hobisch A, Culig Z, Radmayr C, Bartsch G, Klocker H, Hittmair A. Androgen receptor status of lymph node metastases from prostate cancer. Prostate 1996;28:129-35.
-
(1996)
Prostate
, vol.28
, pp. 129-135
-
-
Hobisch, A.1
Culig, Z.2
Radmayr, C.3
Bartsch, G.4
Klocker, H.5
Hittmair, A.6
-
25
-
-
0042978480
-
Androgen receptor gene amplification and protein expression in hormone refractory prostate cancer
-
Edwards J, Krishna NS, Grigor KM, Bartlett JM. Androgen receptor gene amplification and protein expression in hormone refractory prostate cancer. Br J Cancer 2003;89:552-6.
-
(2003)
Br J Cancer
, vol.89
, pp. 552-556
-
-
Edwards, J.1
Krishna, N.S.2
Grigor, K.M.3
Bartlett, J.M.4
-
26
-
-
0036170838
-
Disruption of androgen receptor function inhibits proliferation of androgen-refractory prostate cancer cells
-
Zegarra-Moro OL, Schmidt LJ, Huang H, Tindall DJ. Disruption of androgen receptor function inhibits proliferation of androgen-refractory prostate cancer cells. Cancer Res 2002;62:1008-13.
-
(2002)
Cancer Res
, vol.62
, pp. 1008-1013
-
-
Zegarra-Moro, O.L.1
Schmidt, L.J.2
Huang, H.3
Tindall, D.J.4
-
27
-
-
79960277488
-
Prostate cancer: Abiraterone increases overall survival in men with castration-resistant prostate cancer
-
Fenner A. Prostate cancer: abiraterone increases overall survival in men with castration-resistant prostate cancer. Nat Rev Urol 2011;8:351.
-
(2011)
Nat Rev Urol
, vol.8
, pp. 351
-
-
Fenner, A.1
-
28
-
-
77950267783
-
Hsp27 promotes insulin-like growth factor-I survival signaling in prostate cancer via p90Rsk-dependent phosphorylation and inactivation of BAD
-
Zoubeidi A, Zardan A, Wiedmann RM, Locke J, Beraldi E, Fazli L, et al. Hsp27 promotes insulin-like growth factor-I survival signaling in prostate cancer via p90Rsk-dependent phosphorylation and inactivation of BAD. Cancer Res 2010;70:2307-17.
-
(2010)
Cancer Res
, vol.70
, pp. 2307-2317
-
-
Zoubeidi, A.1
Zardan, A.2
Wiedmann, R.M.3
Locke, J.4
Beraldi, E.5
Fazli, L.6
-
29
-
-
80052256577
-
Clusterin inhibition using OGX-011 synergistically enhances Hsp90 inhibitor activity by suppressing the heat shock response in castrate resistant prostate cancer
-
Lamoureux F, Thomas C, Yin MJ, Kuruma H, Beraldi E, Fazli L, et al. Clusterin inhibition using OGX-011 synergistically enhances Hsp90 inhibitor activity by suppressing the heat shock response in castrate resistant prostate cancer. Cancer Res 2011;71:5838-49.
-
(2011)
Cancer Res
, vol.71
, pp. 5838-5849
-
-
Lamoureux, F.1
Thomas, C.2
Yin, M.J.3
Kuruma, H.4
Beraldi, E.5
Fazli, L.6
-
31
-
-
79955866277
-
Current clinical trials in castrate-resistant prostate cancer
-
Petrylak DP. Current clinical trials in castrate-resistant prostate cancer. Curr Urol Rep 2011;12:173-9.
-
(2011)
Curr Urol Rep
, vol.12
, pp. 173-179
-
-
Petrylak, D.P.1
|